

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>22862-0003US1</b>	Application No. <b>10/598,486</b>
	Applicant <b>Yu et al.</b>		
	Filing Date <b>August 31, 2006</b>	Group Art Unit <b>1644</b>	

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,844,075	12/01/1998	Kawakami et al.			
	2	6,010,905	01/04/2000	Cohen et al.			
	3	2002/0182194	12/05/2002	Ju et al.			
	4	2003/0064916	04/03/2003	Sherman			
	5	2010/0135975	06/03/2010	Yu et al.			
	6	2010/0310643	12/09/2010	Singh et al.			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	7	WO 2006/034334	03/30/2006	WIPO				
	8	WO 2010/028066	03/11/2010	WIPO				
	9	WO 2010/129895	11/11/2010	WIPO				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	10	ABDEL-WAHAB et al., "Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity," Cell. Immunol., 186:63-74 (1998)
	11	BODEY et al., "Cyclooxygenase-2 (COX-2) overexpression in childhood brain tumors," In Vivo, 20:519-525 (2006)
	12	CASEY et al., "Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine," Immunology, 110:105-111 (2003)
	13	CHO et al., "Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas," Cell Transplant., 18:977-983 (2009)
	14	CZERNIECKI et al., "Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion," Cancer Res., 67:1842-52 (2007)
	15	DAUER et al., "Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells," J. Immunother., 28:332-342 (2005)
	16	DENKERT et al., "Prognostic impact of cyclooxygenase-2 in breast cancer," Clin. Breast Cancer, 4:428-433 (2004)
	17	GASPARINI et al., "Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?" Lancet Oncol., 4:605-615 (2003)
	18	IRVIN et al., "T cells enhance stem-like properties and conditional malignancy in gliomas," PLoS One, 5:e10974 (2010)
	19	KUBY et al., Immunology, W. H. Freeman and Co., pp. 523-524 (1992)

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <b>22862-0003US1</b>	Application No. <b>10/598,486</b>
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant <b>Yu et al.</b>	
		Filing Date <b>August 31, 2006</b>	Group Art Unit <b>1644</b>

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	20	LEFRANC, "Editorial: On the road to multi-modal and pluri-disciplinary treatment of glioblastomas," Acta Neurochir. (Wien), 151:109-112 (2009)
	21	LIAO et al., "Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?" Drugs, 67:821-845 (2007)
	22	LIU et al., "Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma," Mol. Cancer, 5:67 (2006)
	23	LIU et al., "Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma," Cancer Control, 10:138-147 (2003)
	24	LIU et al., "Chemoresistance of stem-like cells isolated from glioblastoma," Proc. Amer. Assoc. Cancer Res., 47:75, abstract #320 (2006) (cited in 22862-0006EP1)
	25	LIU et al., "AIM-2: a novel tumor antigen is expressed and presented by human glioma cells," J. Immunother., 27:220-226 (2004)
	26	LIU et al., "HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells," Cancer Res., 64:4980-86 (2004)
	27	MELCHER et al., "Dendritic cells for the immunotherapy of cancer," Clin. Oncol., 14:185-192 (2002)
	28	OGINO et al., "Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer," Clin. Cancer Res., 14:8221-27 (2008)
	29	OHNO et al., "Multiple roles of cyclooxygenase-2 in endometrial cancer," Anticancer Res., 25:3679-87 (2005)
	30	PARMIANI et al., "Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?" J. Natl. Cancer Inst., 94:805-818 (2002)
	31	PARNEY et al., "Glioma immunology and immunotherapy," Neurosurgery, 46:778-791 (2000)
	32	SOLING et al., "Dendritic cell therapy of primary brain tumors," Mol. Med., 7:659-667 (2001)
	33	SOUMAORO et al., "Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer," Clin. Cancer. Res., 10:8465-71 (2004)
	34	TAKAGI et al., "Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells," Cancer Lett., 213:49-55 (2004)
	35	WESTPHAL et al., "Other experimental therapies for glioma," Recent Results Cancer Res., 171:155-164 (2009)
	36	YANG et al., "Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme," J. Neurosurg., 100:310-319 (2004)
	37	YOUNG et al., "Cyclooxygenase-2 in cervical neoplasia: a review," Gynecol. Oncol., 109:140-145 (2008)
	38	YUAN et al., "Isolation of cancer stem cells from adult glioblastoma multiforme," Oncogene, 58:9392-9400 (2004)
	39	ZAGZAG et al., "Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain," Lab. Invest., 85:328-341 (2005)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	